156 related articles for article (PubMed ID: 33427358)
1. The importance of smoking status at diagnosis in human papillomavirus-associated oropharyngeal cancer.
Liu HY; Daniels CP; Trada Y; Bernard A; You KH; Brown E; Foote M; McGrath M; Ladwa R; Panizza BJ; Porceddu SV
Head Neck; 2021 May; 43(5):1440-1450. PubMed ID: 33427358
[TBL] [Abstract][Full Text] [Related]
2. Impact of Smoking on Outcomes of HPV-related Oropharyngeal Cancer Treated with Primary Radiation or Surgery.
Vawda N; Banerjee RN; Debenham BJ
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1125-1131. PubMed ID: 30513378
[TBL] [Abstract][Full Text] [Related]
3. Smoking cessation is associated with improved survival in oropharynx cancer treated by chemoradiation.
Platek AJ; Jayaprakash V; Merzianu M; Platek ME; Cohan DM; Hicks WL; Marimuthu SP; Winslow TB; Gupta V; Arshad H; Kuriakose MA; Dibaj S; Marshall JR; Reid ME; Warren GW; Singh AK
Laryngoscope; 2016 Dec; 126(12):2733-2738. PubMed ID: 27346612
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project.
Lassen P; Lacas B; Pignon JP; Trotti A; Zackrisson B; Zhang Q; Overgaard J; Blanchard P;
Radiother Oncol; 2018 Jan; 126(1):107-115. PubMed ID: 29100700
[TBL] [Abstract][Full Text] [Related]
5. Adverse effect of smoking on prognosis in human papillomavirus-associated oropharyngeal carcinoma.
Liskamp CP; Janssens GO; Bussink J; Melchers WJ; Kaanders JH; Verhoef CG
Head Neck; 2016 Dec; 38(12):1780-1787. PubMed ID: 27248701
[TBL] [Abstract][Full Text] [Related]
6. Impact of active smoking on outcomes in HPV+ oropharyngeal cancer.
Xiao R; Pham Y; Ward MC; Houston N; Reddy CA; Joshi NP; Greskovich JF; Woody NM; Chute DJ; Lamarre ED; Prendes BL; Lorenz RR; Scharpf J; Burkey BB; Geiger JL; Adelstein DJ; Koyfman SA
Head Neck; 2020 Feb; 42(2):269-280. PubMed ID: 31769100
[TBL] [Abstract][Full Text] [Related]
7. The declining role of post-treatment neck dissection in human papillomavirus-associated oropharyngeal cancer.
Daniels CP; Liu HY; Bernard A; Williams C; Foote MC; Ladwa R; McGrath M; Panizza BJ; Porceddu SV
Radiother Oncol; 2020 Oct; 151():242-248. PubMed ID: 32798595
[TBL] [Abstract][Full Text] [Related]
8. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A
Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522.
Bigelow EO; Harris J; Fakhry C; Gillison ML; Nguyen-Tân PF; Rosenthal DI; Frank SJ; Nair SG; Bahig H; Ridge JA; Caudell J; Donaldson C; Clifford BT; Shenouda G; Birrer MJ; Chen Y; Le QT
Head Neck; 2022 Jan; 44(1):158-167. PubMed ID: 34729846
[TBL] [Abstract][Full Text] [Related]
10. Impact of smoking on stage-specific survival in human papilloma virus-associated oropharyngeal squamous cell carcinoma.
Horwich P; Gundale A; Patin S; Flores J; Moore Medlin T; Chang BA; Nathan CO
Head Neck; 2021 Sep; 43(9):2698-2704. PubMed ID: 34002904
[TBL] [Abstract][Full Text] [Related]
11. Survival advantage in patients with human papillomavirus-driven oropharyngeal cancer and variation by demographic characteristics and serologic response: Findings from Head and Neck 5000.
Whitmarsh A; Pring M; Thomas SJ; Waylen A; Ness AR; Dudding T; Pawlita M; Brenner N; Waterboer T; Schroeder L
Cancer; 2021 Jul; 127(14):2442-2452. PubMed ID: 33721332
[TBL] [Abstract][Full Text] [Related]
12. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.
O'Sullivan B; Huang SH; Siu LL; Waldron J; Zhao H; Perez-Ordonez B; Weinreb I; Kim J; Ringash J; Bayley A; Dawson LA; Hope A; Cho J; Irish J; Gilbert R; Gullane P; Hui A; Liu FF; Chen E; Xu W
J Clin Oncol; 2013 Feb; 31(5):543-50. PubMed ID: 23295795
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of additional HPV diagnostics in 102 patients with p16-stratified advanced oropharyngeal squamous cell carcinoma.
Weiss BG; Anczykowski MZ; Küffer S; Spiegel JL; Bertlich M; Canis M; Ihler F; Kitz J; Jakob M
Eur Arch Otorhinolaryngol; 2021 Jun; 278(6):1983-2000. PubMed ID: 32814982
[TBL] [Abstract][Full Text] [Related]
14. Smoking and other patient factors in HPV-mediated oropharynx cancer: A retrospective cohort study.
Schostag K; Lynch PT; Leavitt T; Sumer BD; Yang A; Shah A; Emmet TR; Sher DJ; Day AT
Am J Otolaryngol; 2022; 43(5):103555. PubMed ID: 36037765
[TBL] [Abstract][Full Text] [Related]
15. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas.
Huang SH; Xu W; Waldron J; Siu L; Shen X; Tong L; Ringash J; Bayley A; Kim J; Hope A; Cho J; Giuliani M; Hansen A; Irish J; Gilbert R; Gullane P; Perez-Ordonez B; Weinreb I; Liu FF; O'Sullivan B
J Clin Oncol; 2015 Mar; 33(8):836-45. PubMed ID: 25667292
[TBL] [Abstract][Full Text] [Related]
16. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
17. Rethinking the 10-pack-year rule for favorable human papillomavirus-associated oropharynx carcinoma: A multi-institution analysis.
Broughman JR; Xiong DD; Moeller BJ; Contrera KJ; Prendes BL; Lamarre ED; Ku JA; Burkey BB; Woody NM; Joshi NP; Adelstein DJ; Geiger JL; Frenkel CH; Milas ZL; Brickman DS; Sumrall AL; Carrizosa DR; Greskovich JF; Koyfman SA; Ward MC
Cancer; 2020 Jun; 126(12):2784-2790. PubMed ID: 32167593
[TBL] [Abstract][Full Text] [Related]
18. HPV status and therapeutic initial strategy impact on survival and oncologic outcomes: 5-year results from the multicentric prospective cohort of oropharyngeal cancers Papillophar.
Culié D; Rousseau A; Pretet JL; Lacau Saint Guily J
Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):3071-3078. PubMed ID: 34661716
[TBL] [Abstract][Full Text] [Related]
19. 20 pack-year smoking history as strongest smoking metric predictive of HPV-positive oropharyngeal cancer outcomes.
Chen SY; Last A; Ettyreddy A; Kallogjeri D; Wahle B; Chidambaram S; Mazul A; Thorstad W; Jackson RS; Zevallos JP; Pipkorn P
Am J Otolaryngol; 2021; 42(3):102915. PubMed ID: 33482566
[TBL] [Abstract][Full Text] [Related]
20. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
